Our R&D activities are focused on developing innovative in vitro tools for ADME-monolayer assays, as well as major efflux and uptake transporters and toxicity-metabolism.
Currently, ReadyCell R&D Department is working in the development and launch of the following products:
All FDA and EMA recommended and mandatory cellular models in ready-to-use formats.
iPS derived cellular lines (cardiomyocytes, neurons, hepatocytes) in ready-to-use format.
3D models in ready-to-use format